SM
RAPT

SG3 Management’s RAPT Therapeutics RAPT Stock Holding History

SG3 Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,500
Closed -$661K – 1204
2021
Q2 		$636K Buy
2,500
+2,000
+400% +$374K 0.02% 599
2021
Q1 		$89K Buy
+500
New +$82.4K ﹤0.01% 1057

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

SG3 Management's RAPT Position: Q3 2021 in Review

SG3 Management sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 2,500 shares — an estimated $661K sold.

SG3 Management first reported a position in RAPT in Q1 2021 and held it in 2 quarters. The position peaked at $636K in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

  • SG3 Management reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 2,500 RAPT Therapeutics shares in Q3 2021, an estimated $661K.
  • SG3 Management first reported a position in RAPT Therapeutics in Q1 2021 and held it in 2 quarters.
  • SG3 Management's RAPT Therapeutics position peaked at $636K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.